Stockreport
BioMarin Pharmaceutical reaffirms long-term outlook [Seeking Alpha]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
This includes ~$4B in revenues in 2027; mid-teen CAGR through 2034; and potential treatments for skeletal conditions to become a more than $5B revenue opportunity. The outlook also sees a 40% non-GAAP operating margin starting in 2026 rising to the low- to mid-40% range; and more than $1.25B operating cash flow annually starting in 2027. Earlier in September, BioMarin unveiled a $500M cost transformation program Recommended For You More Trending News Recommended For You More Trending News About BMRN Stock Related Stocks Trending Analysis Trending News
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish [Yahoo! Finance][Yahoo! Finance]
- BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting[PR Newswire]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Scotiabank from $95.00 to $78.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $90.00. They now have an "overweight" rating on the stock.[MarketBeat]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist Financial Co. from $118.00 to $90.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 9/24/24 - Form 8-K
- 9/17/24 - Form 4
- 9/4/24 - Form 8-K
- BMRN's page on the SEC website
- More